Contrary to recent studies that report the identification of new driver mutations in some RHO GTPases members, such as RAC1, RHOA, and CDC42 [32], analysis of cancer genomes has demonstrated that mutations affecting RHO signaling pathways are found at low frequency in a limited spectrum of tumor types [18,21,33]. This evidence concerns the gene RHOA and neoplasm.